|
Psoriasis
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
TNF-α -238 G/A, -308 G/A and -857 C/T polymorphisms could be used to identity individuals with elevated susceptibility to psoriasis in certain populations.
|
31775137 |
2019 |
|
Psoriasis
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Finally, the conjugate exhibited an improved antiproliferation activity in tumor necrosis factor-α-induced HaCaT cells, which is an in vitro psoriasis model.
|
31751564 |
2020 |
|
Psoriasis
|
0.400 |
Biomarker
|
disease |
BEFREE |
Anti-tumor necrosis factor-alpha (TNF-α) immunotherapy has revolutionized the treatment of inflammatory diseases, such as psoriasis and psoriatic arthritis.
|
31719235 |
2020 |
|
Psoriasis
|
0.400 |
Biomarker
|
disease |
BEFREE |
Here, we elucidate the cellular and molecular "scar" and its imprints left after clinical resolution of psoriasis treated with anti-TNFα, anti-IL-17, or anti-IL-23 antibodies or phototherapy.
|
31673756 |
2019 |
|
Psoriasis
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
To examine whether initiation of interleukin (IL)-17, IL-12/23 or tumour necrosis factor (TNF) inhibitor is associated with an increased risk of serious infection among real-world psoriasis (PsO) or psoriatic arthritis (PsA) patients.
|
31672774 |
2020 |
|
Psoriasis
|
0.400 |
Biomarker
|
disease |
BEFREE |
Psoriasis Associated with Tumor Necrosis Factor-Alpha Inhibitors in Children with Inflammatory Diseases.
|
31646743 |
2019 |
|
Psoriasis
|
0.400 |
Biomarker
|
disease |
BEFREE |
TNF inhibitors are also efficacious for other inflammatory joint and spine diseases, and have been approved for inflammatory bowel disease, uveitis and psoriasis.
|
31639514 |
2019 |
|
Psoriasis
|
0.400 |
Biomarker
|
disease |
BEFREE |
The main signalling pathways in psoriasis include TNF-α, IL-23 and IL-17.
|
31639088 |
2019 |
|
Psoriasis
|
0.400 |
Biomarker
|
disease |
BEFREE |
Over the last decades, research advances in understanding the role of tumor necrosis factor alpha (TNF α) and other cytokines in the pathogenesis of psoriasis have driven the introduction of biologic agents targeting specific immune mediators in everyday clinical practice.
|
31623470 |
2019 |
|
Psoriasis
|
0.400 |
Biomarker
|
disease |
BEFREE |
Treatment with GRg1 or DXM significantly mitigates (p < .01) psoriasis area severity index (PASI) score, skin thickness, lipid peroxidation, and inflammatory markers (IL-23, 22, 17A, 1β, and TNF-α).
|
31502279 |
2019 |
|
Psoriasis
|
0.400 |
Biomarker
|
disease |
BEFREE |
In the past decade, biologics targeting tumor necrosis factor-α, interleukin (IL)-23, and IL-17 have been developed and approved for the treatment of psoriasis.
|
31491865 |
2019 |
|
Psoriasis
|
0.400 |
Biomarker
|
disease |
BEFREE |
On the other hand, inhibition of IL-12-IL-23, as compared with inhibition of TNF, has greater efficacy for psoriasis, comparable efficacy for peripheral arthritis, but was ineffective in studies of axial spondyloarthritis.
|
31485004 |
2019 |
|
Psoriasis
|
0.400 |
Biomarker
|
disease |
BEFREE |
The clinical success of biologics that inhibit TNF (Tumor Necrosis Factor) in inflammatory bowel diseases (IBD), psoriasis and rheumatoid arthritis (RA) has clearly established a pathogenic role for this cytokine in these inflammatory disorders.
|
31457011 |
2019 |
|
Psoriasis
|
0.400 |
Biomarker
|
disease |
BEFREE |
Currently, there is no cure for PsO; however, the introduction of biologic therapies has revolutionized the clinical management of patients with PsO by expanding treatment options to include multiple therapies with different mechanisms of action targeting cytokines, including tumor necrosis factor inhibitors (TNFis), interleukin (IL)-17A inhibitors, an IL-12/23 inhibitor, and IL-23 inhibitors.
|
31424708 |
2019 |
|
Psoriasis
|
0.400 |
Biomarker
|
disease |
BEFREE |
A significant increase in PASI 75 (RR: 11.65; 95% CI: 9.01-15.06), PASI 90 (RR: 21.74; 95% CI: 14.28-33.10), PASI 100 (RR: 31.56; 95% CI: 14.66-67.96), PGA 0/1 (OR: 23.21; 95% CI: 14.61-36.89), and DLQI 0/1 (RR: 10.29; 95% CI: 7.52-14.09) was identified for anti-IL-23p19 mAb vs. placebo, and PASI 75 (RR: 1.25; 95% CI: 1.18-1.32), PASI 90 (OR: 2.56; 95% CI: 2.13-3.09), PASI 100 (OR: 2.38, 95% CI: 1.89-2.99), and DLQI 0/1 (RR: 1.33; 95% CI: 1.20-1.47) vs. tumour necrosis factor (TNF) antagonists for the treatment of psoriasis.
|
31389789 |
2019 |
|
Psoriasis
|
0.400 |
Biomarker
|
disease |
BEFREE |
Our findings confirm the importance of TNF-α in psoriasis pathogenesis and a positive correlation with lesions severity.
|
31384319 |
2019 |
|
Psoriasis
|
0.400 |
Biomarker
|
disease |
BEFREE |
Beside TNF-α or IL-23, the IL-17 family is a newer group that has proven implications in the pathogenesis of psoriasis.
|
31384317 |
2019 |
|
Psoriasis
|
0.400 |
Biomarker
|
disease |
BEFREE |
Tumor necrosis factor-α inhibitor-induced psoriasis in juvenile idiopathic arthritis patients.
|
31240749 |
2019 |
|
Psoriasis
|
0.400 |
Biomarker
|
disease |
BEFREE |
Th1, Th17, and Treg Responses are Differently Modulated by TNF-α Inhibitors and Methotrexate in Psoriasis Patients.
|
31101850 |
2019 |
|
Psoriasis
|
0.400 |
Biomarker
|
disease |
BEFREE |
Tumor necrosis factor (TNF) inhibitors account for a large proportion of drugs used to treat psoriasis and are indicated first-line options in certain settings.
|
31094242 |
2019 |
|
Psoriasis
|
0.400 |
Biomarker
|
disease |
BEFREE |
The pro-inflammatory cytokine, TNF-α, which plays a major role in the development and persistence of diseases such as Crohn's disease, psoriasis, psoriatic arthritis, and rheumatoid arthritis, is the basis for the use of anti-TNF-α therapies.
|
31089365 |
2019 |
|
Psoriasis
|
0.400 |
Biomarker
|
disease |
BEFREE |
Tumor necrosis factor (TNF)‑α‑stimulated HaCaT cells and an imiquimod‑induced psoriasis mouse model were used to produce in vitro and in vivo models, respectively.
|
31017270 |
2019 |
|
Psoriasis
|
0.400 |
Biomarker
|
disease |
BEFREE |
Interleukin-17A inhibitors are a promising alternative to tumor necrosis factor-α inhibitors for the treatment of psoriasis.
|
31017250 |
2019 |
|
Psoriasis
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
In PS, there are enhanced type I interferon (IFN), angiogenesis, and over-expression of several proinflammatory cytokines, such as tumor necrosis factor and interleukin (IL)-1 family members generated by several immune cells including MCs.
|
31012218 |
2019 |
|
Psoriasis
|
0.400 |
Biomarker
|
disease |
BEFREE |
Tumor necrosis factor (TNF) α which releases from keratinocytes activates dendritic cells in the early stages of complex pathogenesis of psoriasis.
|
30972872 |
2019 |